and Biogen's lecanemab - could give the medical community a better sense of whether Aduhelm is up to the job of slowing the ravages of Alzheimer's.
"If another independent study of a different anti-amyloid therapy shows a clear clinical benefit, it makes me much more comfortable with continued use of Aduhelm," he said. Large clinical trials of Aduhelm, known chemically as aducanumab, produced contradictory data, with one trial failing and another showing benefit. There was also a potentially serious brain swelling side effect.
"That's not to suggest that the next drug that lowers amyloid is a slam dunk or even gets approved. It may not," he said. Japan's Eisai completed enrollment last month in a pivotal 18-month study of lecanemab in symptomatic early Alzheimer's patients. The drug is also being studied in a large trial of people with evidence of amyloid in their brains who do not yet have symptoms of the disease.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Big insurers are mulling new ways to pay for Biogen's $56,000-per-year Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know. spoiler alert: they'll raise premiums and deductibles along with new exclusions to not pay claims
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »